APN-497444

APN-497444 is an antibody-drug conjugate (ADC) developed by Atreca for oncology indications, specifically targeting a novel, tumor-specific glycan. The drug candidate is designed to bind selectively to tumor cells expressing this glycan, with the goal of delivering a cytotoxic payload directly to cancer cells while sparing normal tissues. Preclinical studies have demonstrated uniform and tumor-selective binding with high target prevalence in colorectal cancer and compelling anti-tumor activity when weaponized as an ADC. The program utilizes Zymeworks’ ZymeLink technology for its conjugation platform[1][3][4][5][6].